AstraZeneca AZN announced that CHMP has recommended approval for its blockbuster cancer drug Imfinzi (durvalumab) as a monotherapy for treating limited-stage small cell lung cancer (LS-SCLC ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi (durvalumab) for approval in the European Union (EU) as a single agent for ...

AstraZeneca, a global, science-led biopharmaceutical company, announced that its Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of ...

The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...

At ASCO, AZ reported the full data from its DUO-O study of PD-L1 inhibitor Imfinzi (durvalumab ... Last year, for example, the label for GSK’s PARP Zejula (niraparib) was narrowed to BRCA ...

The partnership with the streaming platform began in 2019 and was Audiomack’s first licensing deal with a major label. In this expanded agreement, the UK, France, Italy, Germany, the Caribbean ...

AZ believes the unpaid importation taxes stem from its immunotherapy duo Imfinzi and Imjudo, which can be used together to treat liver cancer. The indication has not been approved in mainland China.

If there's one thing the coastline of France has going for it, it's a glamorous reputation. The getaway of choice for members of high society since the 18th century, France is home to prime ...

AstraZeneca’s Imfinzi minimised mortality risk by 27% against a placebo. Credit: © AstraZeneca 2025. The European Medicines Agency’s Committee for Medicinal ...

(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval as a ...